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Abstract 
Jordana Baden. Mapping the transcriptional start site(s) of the 
cannabinoid receptor gene. (Under the direction of Dr. Lisa Matsuda.) 
The cannabinoid receptor gene has recently been cloned. 
Comparisons of cDNA clones with genomic DNA show that the gene 
consists of a coding region and at least two untranslated 5' exons (A 
and B). Two alternative transcripts, differing in their 5' 
untranslated sequence, have been found that code for identical 
receptors. Primer extension for transcript A reveal that its most 5' 
transcriptional start site corresponds to nucleotide -548. 
Additional transcripts initiated 3' of -548 may exist. Ribonuclease 
protection assay and primer extension for transcript B reveal that 
its most 5' transcriptional start site corresponds to nucleotide 
-406. It is possible that shorter transcripts, corresponding to 




There are three ways to classify cell-surface receptors, as G 
protein-coupled receptors, channel-linked receptors, or catalytic 
receptors (1). Channel-linked receptors alter a cell's permeability 
to specific ions. Upon binding of their ligand, the receptor's 
conformation is changed to create an open tunnel which allows 
specific ions to enter the cell. The signaling of th is type of receptor 
IS extremely rapid and channel-linked receptors are mainly involved 
in synaptic signaling between two electrically excitable cells (1). 
Catalytic receptors can be described as membrane-bound 
enzymes. Ligand binding causes the cytoplasmic portion of the 
receptor to exert a specific action within the cell. To date~ the 
majority of catalytic receptors have cytoplasmic domains which 
function as a tyrosine-specific protein kinase (1). 
G protein-coupled receptors are the most complex class of 
membrane bound receptors. They can positively or negatively effect 
a variety of channels or enzymes in the cell through their unique 
second messenger system. After a ligand binds to these receptors J a 
conformational change occurs which causes an increase in affinity 
between the cytoplasmic domains of the receptor and a G protein. 
The G protein is a heterotrimeric protein consisting of (from highest 
molecular weight to lowest) Ga , G~ and Gy. Ga contains a binding 
site for guanine nucleotides and has GTPase activity (2). In their 
basal state, the three subunits are bound to each other and GDP is 
bound to Ga. Following the receptor's conformational change, the 
receptor binds with the membrane bound G protein which causes the 
Ga subunit to release GDP, in exchange for GTP. The G protein then 
disassociates from the receptor causing a decrease in the affinity 
between the receptor and its ligand. The activated G protein can then 
activate or inactivate membrane bound enzymes or channels. These 
enzymes can alter the concentration of specific molecules such as 
calcium ions or cAMP which affect a variety of cellular responses. 
Marijuana's receptor-mediated mechanisms of action 
Marijuana has been used recreationally and therapeutically for 
centuries. However, it was not until thirty years ago that its 
primary psychoactive compound, L\9-tetrahydrocannabinol (L\9-THC) 
was isolated (Figure 1) (3). Subsequent to the isolation of L\~-THC 
researchers focused on characterizing the effect of L\9-THC and its 
metabolites (cannabinoids) on a variety of whole animal models. 
Although these effects vary greatly depending upon the 
concentration, the type of cannabinoid tested, and the animal model, 
low doses tend to cause a mixture of depressant and stimulatory 
effects whereas higher doses cause central depression (4,5). 
The first evidence that the effects from lower concentrations 
of cannabinoids might be the result of a receptor-based mechanism 
came from an experiment which tested enantiomers of L\9-THC on 
dogs (6). L\9-THC exists in two forms that differ only by their chiral 
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Figure 1: Naturally occuring cannabinoid agonists. ~9-THC is numbered in 
accordance with the dibenzopyran system. 
the two enantiomers on dogs, Adams discovered that the effect of 
~9-THC were stereoselective (6). The enantiomer with chiral 
centers in the trans position, (-)d9-THC, was significantly more 
potent in eliciting dog ataxia, a characteristic response to 
cannabimimetic compounds. 
For the next several years, researchers tried to 
pharmacologically characterize the binding site of cannabinoids. 
Through their structure-activity relationship studies, Binder and 
Franke provided further evidence that a receptor existed for 
cannabinoids (7). They observed that very little change could be 
made on the d9-THC molecule without causing complete loss of 
psychotropic activity. Several other studies also involved changing 
moieties on cannabimimetic compounds and assessing their potency 
to elicit a characterized response (See ref. 8 for review). One such 
study which assessed the analgesic potency of altered cannabinoids 
reported that the important functional groups for eliciting Iqw 
dosage effects were the phenolic A ring hydroxyl and the A ring alkyl 
side chain (Figure 1) (9). 
Binding studies involving natural cannabinoids were difficult 
to perform due, in part, to physical characteristics of the classical 
cannabinoids. d9-THC and its metabolites tend to be lipophilic and 
adhere to glass and plastic ware (10). The elucidation of the binding 
site for cannabinoids was made possible by the synthesis of several 
cannabinoid analogs such as WIN 55,225, CP-55,940, and 
levonantradol (11). In 1988. Devane et al. characterized the 
cannabinoid binding site using tritiated CP-55,940 in a 
centrifugation assay (12). This study demonstrated that a specific, 
4 
saturable cannabinoid binding site existed in brain tissue (12). 
Additionally, Devane et al. reported that ligand binding was 
decreased by a nonhydrolyzable GTP analog (12). This decrease in 
binding affinity is characteristic of binding to a G protein-coupled 
receptor. 
Additional evidence that the cannabinoid receptor was a G 
protein-coupled receptor was provided by other studies which used 
synthetic cannabinoid analogs (9,13). Howlett et al. reported that in 
a neuroblastoma cell line, cannabinoids inhibit adenylyl cyclase (9, 
13). This inhibition of adenylyl cyclase appeared to be mediated 
through a receptor coupled to a G protein since the inhibition 
required GTP and was pertussis-toxin sensitive (9, 13). 
The cannabinoid receptor, like other G protein-coupled 
receptors, has seven transmembrane domains composed of 
hydrophobic amino acids (1). It has an intracellular C terminus and 
an extracellular N-terminus. Translation of the rat cannabinoid 
receptor eDNA predicts that the receptor contains 473 amino acids 
(14). There are potential sites for N-linked glycosylation on 
residues 78 and 84 (14). From the amino acid sequence it is 
predicted that the receptor would have a molecular mass of 52,844 
daltons. However, the actual molecular weight is most likely larger 
due to the likelihood of glycosylation (14). 
In addition to its negative coupling to adenylyl cyclase, the 
cannabinoid receptor is known to couple also to potassium and 
calcium channels. The cannabinoid receptor has been shown to 
decrease calcium conductance in the neuroblastoma x glioma hybrid 
cell line, NG108-15 (15, 16). Potassium channels are also positively 
5 
coupled to cannabinoid receptors In cultured hippocampal neurons 
(17) . 
Recently, an endogenous ligand for the cannabinoid receptor, 
anandamide, an arachidonic acid derivative (Figure 1), was reported 
by Devane et al. (18). Their study tested the ability of porcine brain 
fractions to displace a radio-labeled cannabinoid analog in a 
centrifugation-based ligand binding assay. 
Cloning and characterization of the cannabinoid receptor 
gene 
In 1990, the cannabinoid receptor gene was cloned in rats. In 
an attempt to find a novel G protein-coupled receptor, Matsuda et al. 
(19) used a probe that was based on sequence encoding the second 
membrane-spanning domain of the substance K receptor. The choice 
to use a probe based on this particular receptor was quite simple 
owing to the fact that, at the time, this was the only neural peptide 
receptor that had been cloned (15). The second membrane spanning 
domain is known to be quite conserved among many families of G 
protein-coupled receptors. The probe was hybridized to a rat 
cerebral cortex cDNA library under low stringency conditions. This 
allowed binding of the probe to similar sequences that putatively 
encoded a membrane spanning domain of a novel G protein-coupled 
receptor. This strategy detected a clone, SKR6, the sequence of 
which was indicative of a G protein coupled-receptor. 
Determination that SKR6 was a cannabinoid receptor clone 
came through the fortuitous discovery that two cell lines known to 
contain cannabinoid receptors expressed the SKR6 gene (19). 
6 
Furthermore, a cell line which was known not to contain cannabinoid 
receptors did not express the SKR6 gene (19). Additional evidence 
that SKR6 coded for a cannabinoid receptor was provided when the 
localization of SKR6 RNA and cannabinoid receptors in rat brain 
were compared and observed to be similar (19). Transfection of a 
cell line which did not contain cannabinoid receptors with the SKR6 
clone and subsequent exposure to cannabinoids resulted in an 
inhibition of adenylyl cyclase (19). This provided conclusive 
evidence that the SKR6 clone coded for a cannabinoid receptor. 
Soon after the cloning of the rat cannabinoid receptor, BS08, a 
human cannabinoid receptor cDNA was reported (20). The human and 
rat cDNAs code for proteins with an amino acid identity of 97%, yet 
their untranslated 5' regions were notably dissimilar. To determine 
if the variation in the 5' untranslated sequence was due to species 
differences, rat and human genomic DNA was sequenced. Both the 5' 
untranslated 8808 sequence (herein referred to as exon 8) and the 5' 
untranslated SKR6 sequence (herein referred to as exon A) were 
found on human and rat genomic DNA (T.I. Bonner, unpublished data). 
Exon B was upstream of exon A and the two were separated by 
several kilobases (T.I. Bonner, unpublished data). Sequencing of 
genomic DNA also revealed that the coding exon of the cannabinoid 
receptor gene contains 63 bp of 5' untranslated sequence, the protein 
coding region, and 3.7 kilobases of untranslated sequence (T.I. 
Bonner, unpublished data). Using this data, a model of the 
cannabinoid receptor gene can be constructed (Figure 2). 
The alternative 5' regions of the rat and human clones are not 
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Figure 2: A model of the rat cannabinoid receptor gene (not drawn to scale). 
result of alternative 5' exons. Thus, at least two transcripts that 
encode for the same cannabinoid receptor exist. By studying the 
different sequences of the transcripts, certain characteristics can 
be examined such as the half lives of the transcripts or whether the 
RNA (and consequently the protein) is preferentially localized within 
the cell. Moreover, the rate at which the transcripts are translated 
can be quantitated. Important aspects regarding the regulation of a 
gene's expression can also be ascertained by analyzing upstream 
genomic sequence. Gene expression may be induced or repressed in a 
time-dependent manner. Similarly, it is possible that the gene is 
preferentially expressed in certain tissues. In order to investigate 
these issues, two factors must first be determined: the start site of 
each of the transcripts and the sequence differences in the 
transcripts. The objective of this project is to determine the 
sequences and start sites of the alternative transcripts encoding the 
cannabinoid receptor. 
9 
Strategy and Experimental Procedures 
The original strategy used to map the transcriptional start 
site was to generate transcripts encompassing the entire 5' end of 
the cannabinoid receptor gene using RACE (Rapid Amplification of 
cDNA Ends) (21, 22), and then subclone and sequence the transcripts. 
Ribonuclease protection assays and primer extensions would then be 
used to confirm the results. 
RACE was first described by M. Frohman (21) in order to 
provide information on the 5' or 3' end of cDNA. RACE is similar to 
the more traditional primer extension mapping method in that a 
cDNA is synthesized or "extended" from an RNA template by reverse 
transcriptase and a primer specific for the gene. Unlike primer 
extension, RACE amplifies the cDNA by PCR through a series of 
denaturing, annealing and extension steps. Two sets of primers are 
used in the amplification, gene specific primers (GSP-1 and GSP-2), 
and RACE primers (Ri, Ro, Ri/Ro-TTTT). These primers are nested 
such that the two rounds of amplification not only increase the yield 
of eDNA but increase its specificity as well. A diagram of RACE is 
shown in figure 3. 
A second strategy to generate RACE products is described by 
Edwards et al. (22). This strategy (herein referred to as RACE-2) 
differs from Frohman's original RACE strategy (herein referred to as 
RACE-1) in the method employed to supply necessary, known 
sequence on the 3' end of the reverse transcribed cDNA; RACE-1 
achieves this by using terminal dideoxytransferase (TOT) to add a 
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Figure 4: A diagram of RACE-2 
initial template to amplify the leader sequences of both 5' exons. 
Additionally, a second cDNA pool was synthesized using random 
hexamers. This has been shown to increase the probability of 
producing a cDNA from a relatively rare RNA (24). The cDNA to be 
used for RACE-1 was treated with RNAse H to degrade the RNA 
hybridized to the first strand cDNA, poly-A tailed, and purified uSing 
the Spin-Bind Purification system (FMC). For RACE-2, the RNA was 
hydrolyzed with NaOH and the cDNA was cleaned with the "Geno-
Bind" system (Clontech). The anchor was then ligated to the RACE-2 
cDNA. 
Amplification of cDNA 
Using the OLIGO 4.0 program for Macintosh and putative 
sequence from exon A and exon B (T.1. Bonner, unpublished), gene 
specific primers were selected. Primers for RACE-1 were chosen 
that had a similar melting temperature to that of Ro-RiTTT, Ro, or 
Ri. Primers for RACE-2 were chosen that had a similar melting 
temperature to that of the anchor primer. All primers were analyzed 
to ensure that they would not form stable hairpins or stable dimers 
with the other primers (Figure 5 and Table 1). For RACE-1 10 ].11 of 
cDNA was amplified in a 50 J.l1 reaction. The basic reaction mixture 
contained 1 X peR buffer, 25 ~M primers, 0.2 mM dNTPs, and 2.5 units 
Taq DNA Polymerase (Gibeo). First round amplification products 
were diluted 1 :20 and were used as template for the second 
amplification cycle. Anchor-ligated cDNA to be used for RACE-2 
was amplified in the same manner with the exception of a lower 
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Figure 5: Location and size of primers and probes. Numbers refer to base pairs J with -1 designating the most 3' 









































1 Used for reverse transcription of cDNA 
2 Used for PCR 
3 Used for RACE-1 
4 Used for RACE-2 
5 Used for sequencing 
6 Used for primer extension 





















was performed in RACE-2. Products were analyzed by 
electrophoresis on a 4% polyacrylamide gel. The gels were stained 
with ethidium bromide and photographed. 
Subcloning RACE products 
Amplification products were treated with Klenow and cut with 
a restriction enzyme (Xho I) the recognition site for which was 
included in the sequence of the Ri primer. The plasmid, Bluescript II 
SK (pBS), was cut with Sma I and Xho I, combined with the RACE 
products, and the DNA ligated overnight. Competent E. coli (XL-1 
blue) were transformed and colonies containing the desired plasmid 
were identified by Southern blot analysis of miniprep DNA (25). 
Miniprep DNA was cut with Xho I or BamHI to linearize the plasmid 
and Xho 1 and BamHI to isolate the insert. The DNA was 
electrophoresed on a 1 .2% agarose gel. Southern blots were prepared 
from the gels as described by Maniatis et al. (26). Blots were 
prehybridized for 2 hours (600 C, 6X SSG and 5X Denhardt's), 
hybridized for 3 hours (60 0 G, 6X SSC, 3X Denhardt's, 500,000 
DPM/ml of a 32p labeled 39mer oligonucleotide probe [Figure 5 and 
Table 1]) and washed (4 X 20 minutes, 600 C, IX SSC). Blots were 
exposed to film with enhancing screens (24-72 hours). Additional 
DNA from clones that hybridized with the probes were obtained by 
cesium chloride density gradient plasmid isolation. 
Sequencing plasmids 
The subcloned DNA was sequenced by the chain-termination 
method of Sanger et al. (27) using the Sequenase Version 2.0 system 
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(USB). Plasmids were denatured with alkali, precipitated and then 
annealed with primers specific for pBS. The primers were extended 
with the Sequenase Polymerase, deoxynucleoside triphosphates~ and 
35S dATP. The addition of dideoxynucleoside triphosphates 
terminates the extension reactions. Sequencing reactions were 
analyzed on 6-8% polyacrylamide, 7M urea denaturing gel. The gel 
was fixed (15 minutes) in 10% methanol, 10% acetic acid, dried (30 
minutes) and exposed to film (3-7 days). 
Verification of Start Site Identified by RACE: 
Primer Extension 
Primers specific for exon A (39mer A) or exon B (39mer B) 
(Figure 5 and Table 1) were chosen which begin approximately 100 
base pairs 3' of the putative transcriptional start sites of their 
respective exons. Total cerebellar RNA (12.5 I1g) was denatured 
(650 C, 5 minutes) and a reaction mixture containing AMV-RT, 1 X 
reverse transcription buffer, 12.5 11M primer, 0.2 mM dATP, 0.2 mM 
dGTP, 0.2 mM dTTP, .02 mM dCTP and 65 J-lCi 32p-dCTP was added. 
The reaction mixture was incubated (420 C, one hour) and passed 
through a G50 column. The labeled cDNA (100,000 DPM) was 
denatured and electrophoresed on a 8% polyacrylamide 7M urea gel. 
.. 
Sequencing reactions of genomic DNA primed with 39mer A or 39mer 
B were electrophoresed next to either the exon A or exon B primer 
extension product, respectively. The gel was fixed (15 minutes) in 
10% methanol, 100/0 acetic acid, dried (30 minutes) and exposed to 
film with enhancing screens (1-7 days). 
1 8 
Ribonuclease Protection Assay 
Genomic DNA flanking the sequence from both exons is 
available (T.I. Bonner, unpublished data) and it is from this genomic 
DNA that the probes for the protection assay were derived. A 
genomic DNA fragment (Sau96 I/Hinc II) was inserted into pBS at the 
Eco RV and Hinc II sites. The Hinc II site of this genomic fragment 
is located 68 bp upstream from the 3' end of exon A, and the Sau 96 I 
site is 320 bp further upstream (T.I. Bonner, unpublished data). The 
resultant plasmid, pSL, was used to generate the probes for 
protection assay of transcript A. pSL (2).1g) was cut with Xho I or 
EcoRI. The antisense probe was transcribed from the Eco RI cut 
plasmid using T7 RNA polymerase. To generate the sense probe, the 
Xho I treated plasmid was transcribed with T3 RNA polymerase. 
Plasmids pAS and pA6 were used to determine the transcriptional 
start site of exon B. pA5 contains genomic sequence (Msc IIEeo NI) 
which resides in pBS between the Hinc II and Xho I sites. The Eco NI 
site is found 69 bases upstream of the 3' end of exon B and the Mse 
site is approximately 800 bases further upstream (T.I. Bonner, 
unpublished data). Three hundred bases (Bst XI/Sty I) were removed 
from the 5' end of the pAS insert to yield pA6. The antisense probe 
for exon B was generated from pAS (2).1g) cut with Pie I and 
transcribed with T7 RNA polymerase. The sense probe was 
transcribed from 2).1g of pA6 cut with Xho I and transcribed with T3 
RNA polymerase. Transcription of the plasmids was done in the 
presence of 30 ).1ei 32P-UTP, The reaction was treated with DNAse 
and probes were electrophoresed on a 40/0 polyacrylamide, 7M urea 
gel. The probes were cut from the gel after visualization on a film 
1 9 
autoradiograph. The probes were eluted overnight (370 C) in 500 ~I 
0.5 M ammonium acetate, 1 mM EOTA, 0.1 % 80S. The labeled probe 
(100,000 - 300,000 DPM) was then hybridized to 45 - 1 00 J.l9 of 
either cerebellar RNA or tRNA (850 C, 10 minutes; 500 C, overnight). 
The hybridization reaction was then treated with RNAse T1 and 
RNAse A and incubated (370 C, 30 minutes). The RNases were 
inactivated by mixing the reaction with an equal volume of 4M GnTC/ 
0.1 M ~-mercaptoethanol. The reaction was then precipitated with 
isopropanol. The pellet was resuspended in 5 J-li formamide loading 
buffer and denatured. The reactions were electrophoresed on a 4% 
polyacrylamide, 7M urea gel. The gel was fixed (15 minutes) in 10% 
methanol, 10% acetic acid, dried (30 minutes) and exposed to film 
with enhancing screens (7-10 days). 
peR analysis transcript B 
Ribonuclease protection assay for exon A could not distinguish 
a transcript whose leader sequence contains sequence exclusively 
from exon A from a transcript which contains sequences from both 
exon A and exon 8 due to splicing. In order to insure that no such 
transcript exists, PCR analysis using an antisense primer from the 
5' end of the coding region (SKR62) with sense primers specific for 
exon B sequence (S82 [Figure 4 and Table 1]) was carried out on 
brain-derived cDNAs. The thermocycling conditions were: 1000 C 
(45 seconds), 750 C (45 seconds), 720 C (1 minute) repeated for 35 
cycles followed by a final extension period (720 C, 7 minutes). 
20 
Resu Its 
The A RACE-1 product was about 300 base pairs. Subcloning of 
A RACE-1 products was attempted several times and miniprep DNA 
from numerous transfected colonies were analyzed by Southern 
blotting to ascertain that the correct RACE product was present. Of 
the dozens of putative A clones analyzed only 3 hybridized to the 
exon A specific probe (39mer A). 
The three A clones were sequenced (both strands) and one of 
the clones corresponded to known genomic sequence. From this 
clone we ascertained that the transcriptional start site of exon A IS 
-472. These data suggest that exon A is 409 bp. 
Primer extension analysis of cerebellar RNA primed with 
39mer A, however, did not confirm the data provided by the A RACE-
1 product. The 39mer A primer begins at nucleotide -378. Thus, if 
exon A begins at -472, a 94 bp extension product would be present. 
As seen in Figure 6, a primer extension product was detected at 170 
bp. This corresponds to a start site of -548. Additional primer 
extension products corresponding to transcriptional start sites of 
-547 and -545 could also be detected (data not shown). It is not 
known why the A RACE-1 product was truncated at its 5' end, 
however, since a primer extension product of 94 bp was not detected 
the transcriptional start site of -472 is most likely incorrect. 
Protection assay of exon A was unsuccessful. This may be explained 
by the fact that the expression of transcript A is notably low in 
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Figure 6: Autoradiograph of primer extension for transcript A primed 
with 39merA. Sequencing reaction lanes are A, C, G, T. 
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AACTAGGAGTAGCCGACCTCCGAGGTCCCCACAGGACTGTCTGATTTAAAG 
-548 --------------------------------------------------- -498 
TTGATCCTCATCGGCTGGAGGCTCCAGGGGTGTCCTGACAGACTAAATTTC 
TGCTGGTCTTCTAATCCCAGCTTTTGACAATTTGAAAGGGAGATAGATCTA 
-497 --------------------------------------------------- -447 
ACGACCAGAAGATTAGGGTCGAAAACTGTTAAACTTTCCCTCTATCTAGAT 
CTGATCGATTTTTCTCTGTCCCCTCCTCCCTCCCTTGCCCCTCCCTACCCC 
-446 --------------------------------------------------- -396 
GACTAGCTAAAAAGAGACAGGGGAGGAGGGAGGGAACGGGGAGGGATGGGG 
ACCTTCTCTAGCTCAGTTAGGAGCAATTCTATCAAAATGAAAGGCCGCGAA 
-395 --------------------------------------------------- -345 
TGGAAGAGATCGAGTCAATCCTCGTTAAGATAGTTTTACTTTCCGGCGCTT 
TACTTTCTTAACTGAGAGAAATATTTTTTTCTGATTACGTCCACAGAGGAA 
-344 --------------------------------------------------- -294 
ATGAAAGAATTGACTCTCTTTATAAAAAAAGACTAATGCAGGTGTCTCCTT 
CAGAATGCGTGCACCTCTAGCATGCTAAGCAGCACACACTGCAGGCTGTTG 
-293 --------------------------------------------------- -243 
GTCTTACGCACGTGGAGATCGTACGATTCGTCGTGTGTGACGTCCGACAAC 
GTTTAGGCACACGAGCAGTTGCTGTGGCTGGGAAAGAGGCTTCATGTTGAC 
-242 --------------------------------------------------- -192 
CAAATCCGTGTGCTCGTCAACGACCCCGACCCTTTCTCCGAAGTACAACTG 
ATGGTTTAAAAAAAGAAAAAAGRAAAAACCTAATCATTTTAGGKCGTTAGG 
-191 --------------------------------------------------- -141 
TACCAAATTTTTTTCTTTTTTCYTTTTTGGATTAGTAAAATCCMGCAATCC 
AGAACTTACTGTGAACAGGCYCYTTTATTTCTTCAAAAGATGTCTCCCATT 
-140 --------------------------------------------------- -90 
TCTTGAATGACACTTGTCCTRGRAAATAAAGAAGTTTTCTACAGAGGGTAA 
TCAAGCAAGGAGCACCCATGGCTGAG 
-89 --------------------------- -64 
AGTTCGTTCCTCGTGGGTACCGACTC 
Table 2: Sequence of exon A. Sequence obtained from RACE product 
includes nucleotides -472 to -212. Additional sequence obtained 
from genomic DNA sequences (T.1. Bonner, unpublished data). 
23 
the most 5' transcriptional start site of exon A is -548 and its 
length is 485 bp (Figure 9). The full sequence of exon A is shown In 
Table 2. 
RACE of transcript B did not yield interpretable data. 
Northern analysis data revealed transcript B was approximately 6 kb 
(L.A. Matsuda, unpublished data), therefore exon B was less then 1 kb. 
Previous protection probes (pA 1-pA4) showed complete protection 
of the genomic fragment. Therefore, pA5 was the probe which 
contained the putative initiation site with additional 5' flanking 
sequence. The probe used for protection assay of transcript B 
contains 52 bp of vector sequence and 273 bp of genomic DNA 
sequence beginning at nucleotide -467. Ribonuclease protection 
assay of exon B revealed protected fragments of 207 bp, 164 bp, and 
157 bp (Figure 7). These bands correspond to start sites of -406, 
-363, and -356 respectively. In Figure 7 a band corresponding to 
285 bp can be detected in lane 2. This band is not a true protected 
fragment as it is less than 52 bp shorter than the probe. No RNase 
protection of the sense-strand probe was observed (data not shown). 
Primer extension analysis for transcript B was primed with 39mer 
B. This primer begins at nucleotide -245. Extension products of 161 
bp, 160 bp, and 155 bp are clearly detected (Figure 8). These bands 
correspond to transcriptional start sites of -406, -405, and -400. 
Additionally, shorter products can be seen throughout the lane. This 
may be due to incomplete reverse transcription. Two of the shorter 
bands, 118 and 111, are noted as they correspond to the 












-Figure 7: Autoradiograph of RNase protection assay of exon B. 
Sequencing reaction lanes are A, C, G, T. Lane 1: 25 J..lg cerebellar 
RNA/75 J..l9 tRNA, Lane 2: 50 J..lg cerebellar RNA/50 J..lg tRNA, Lane 3: 
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Figure' 8: Autoradiograph of primer extension for transcript B primed with 
39mer B. Sequencing reaction lanes are A, C, G, T. 
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GGGCTGTGGCGCACGGGTGCTAGAGGCCAGGGAXGCGGGCGCGCAGACCGA 
-406 --------------------------------------------------- -356 
CCCGACACCGCGTGCCCACGATCTCCGGTCCCTYCGCCCGCGCGTCTGGCT 
CTGACTTACTGACCGATCGCCGCGGGCACGCCCCGCTCCACCCCGCCCCGC 
-355 --------------------------------------------------- -305 
GACTGAATGACTGGCTAGCGGCGCCCGTGCGGGGCGAGGTGGGGCGGGGCG 
CGCGCCCCGCGCCGCCTCCCCTGCTCGCTCTCTGCCTCTACCTTCTCCACT 
-304 --------------------------------------------------- -254 
GCGCGGGGCGCGGCGGAGGGGACGAGCGAGAGACGGAGATGGAAGAGGTGA 
TCTTTTCCGCCTCCGCCTCCTTCTGGCTCCCCTGGCGCCAGAGCCTTCCCC 
-253 --------------------------------------------------- -203 
AGAAAAGGCGGAGGCGGAGGAAGACCGAGGGGACCGCGGTCTCGGAAGGGG 
TGGCTCAGGCGGGAGCCTGGGCTGTCTGCAGAGCTCTCGTAGAGTCTGGGGG 
-202 --------------------------------------------------- -152 
ACCGAGTCCGCCCTCGGACCCGACAGACGTCTCGAGAGCATCTCAGACCCC 
GXAAATTTCCTTGTAGCAGAGAGCCAGCCCCTTGGCTGGGCGACAGGTGCC 
-151 --------------------------------------------------- -101 
CYTTTAAAGGAACATCGTCTCTCGGTCGGGGAACCGACCCGCTGTCCACGG 
GAGGGAGCTTCTGGGCCGTGGACCGGGGGATGAGAAG 
-100 ------------------------------------- -64 
CTCCCTCGAAGACCCGGCACCTGGCCCCCTACTCTTC 
Table 3: Sequence of exon B. Sequence obtained from genomic DNA 
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Figure 9: Summary of data. Top drawing: A model of the rat cannabinod receptor 
gene. Middle drawing: A model of transcript A (1 denotes first base of translated 
sequence). Bottom drawing: A model of transcript B. *s denotes possible initiation 
sites corresponding to nucleotides -363 and -356. 
assay. From these data, it appears that the most 5' transcriptional 
start site of exon B corresponds to -406. The full length of exon B 
is 343 bp. The full sequence of exon B is shown in Table 3. A 
summary of these data is shown in Figure 9. 
Amplification of B RACE products was a challenging process. 
The three times B-RACE yielded products were they were seen as 
multiple bands ranging from 300 - 500 base pairs. This difficulty In 
amplification of exon B may be explained by a 27 nucleotide stretch 
which contains only guanidine (G) and cystidine (C) residues (Table 
3). This segment has a T m of 97.50 C and a stable 11 base pair 
hairpin. These 27 bp are also flanked by DNA stretches with a 
notably high (>400/0) GC content. Sequences that are extremely stable 
are often difficult to amplify. Deep vent polymerase (NEB), a high 
temperature polymerase, was tested to allow the denaturing 
temperature to be raised to 1000 C. Testing of the high temperature 
polymerases and a variety of primers on various cDNAs yielded no 
products greater than 100 bp. 
The multiple B RACE-1 products were subcloned and mlnlprep 
DNA from transfected colonies were analyzed by Southern blotting. 
None of the potential B clones hybridized with the exon B specific 
probe (39mer B). 
One of the reasons subcloning may have proved so difficult for 
both A and B RACE-1 products was the subcloning strategy. The 
"adapter primer" used for RACE-1 contains an Xho I site which was 
used to select for the insert. The Xho I site is 3 bases away from 
the end and it is known that Xho I cuts only at 10% efficiency after 
two hours if its recognition site is near the end. In order to 
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ameliorate this potential problem, the incubation time for the Xho 
cut was increased from 1 hour to overnight. Originally, pBS was not 
phosphatase treated and the vector and small insert may have 
recombined during the ligation step. 
Subcloning RACE-2 products would not prove as difficult since 
the anchor contains an Eco RI site for post-amplification cloning. 
This enzyme restricts DNA at >900/0 efficiency within 2 hours when 
its recognition is flanked by only a minimum of additional sequence 
(NEB, product literature). This potentially easier subcloning 
strategy was one of the reasons RACE-2 was attempted. Another 
advantage of RACE-2 is that a homogenous population of cDNA should 
be produced. Unlike the ligation step employed in RACE-2 to supply 
known sequence to the 3' end of the cDNA, the tailing of the cDNA 
employed by RACE-1 potentially generates cDNAs of various lengths. 
Unfortunately, RACE-2 did not generate any product for either of the 
transcripts. Single-stranded ligation often proves difficult and 
most likely was the problem in obtaining results (communication 
with Clontech). 
PCR analysis for the B transcript produced an amplification 
product of a single band of the expected 258 bp (Figure 10). If 
transcripts exist that contain exon A sequences between those of 
exon B and the coding region, additional peR products would be 
expected to be present. These data suggest that transcripts 
containing sequences from both exon A and exon B do not exist for 





Figure 10: Photograph of peR analysis of exon B. Lane 1 : Standard reaction 
mixture, Lane 2: Reaction mixture lacking primer SKR62, Lane 3: Reaction 
mixture lacking cDNA, Lane 4: Reaction mixture lacking primer SB2. 
Discussion 
Assuming there are no 5' exons other than exon A and exon B, it 
IS logical to assume that the two transcripts of the cannabinoid 
receptor gene have separate promoters directing their transcription. 
Alternative promoters provide flexibility in the expression of a gene 
(29). In addition to the possible differences in their expression, the 
transcripts may have inherent differences in their stability, 
translational efficiency and/or subcellular localization. 
Promoters are defined as the sequence of DNA to which the 
RNA polymerase binds (1). Several transcription factors are known 
to interact with the RNA polymerase to initiate transcription (1). 
Transcription factors can be tissue specific and/or specific for a 
particular developmental stage. It is possible that possession of 
alternative promoters allows the cannabinoid receptor gene to be 
expressed in a tissue- or developmental stage-specific manner (29). 
The RNA for the cannabinoid receptor has been found to be 
expressed in a variety of tissues (15). Northern analysis has 
demonstrated that cannabinoid receptor RNA is expressed in brain, 
lung and testis. peR-based analysis detects expression in spleen, 
thymus and some blood cells. Additionally, expression of the 
cannabinoid receptor gene has been found in several cell lines 
including neural cell lines, lung fibroblasts and immune cells. These 
studies have not addressed whether transcript A or B is produced, so 
further studies are necessary to ascertain if either transcript is 
expressed in a tissue-specific manner. 
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Several studies have examined the temporal dynamics of the 
cannabinoid receptor. Using in situ hybridization histochemistry the 
RNA for the cannabinoid receptor has been detected in the embryo as 
early as day 12 in rat brain (30). A study done by Mailleux and 
Vanderhaeghen observed that cannabinoid receptor mRNA decreases 
by 50% in aged rats (31). Whether one transcript is preferentially 
expressed during specific developmental stages, has yet to be 
studied. 
Analysis of rat brain RNA provides evidence that the two 
transcripts are not produced in equal amounts (L.A. Matsuda, 
unpublished data). In situ hybridization histochemistry with probes 
specific for the untranslated 5' portions (leader sequence) of 
transcripts A or B leader sequence has shown that, in rat brain, 
mRNA with the B leader sequence is more abundant than mRNA 
containing the A leader sequence. This may be due to exon 8's 
promoter being stronger than exon A's promoter. The transcript for 
the amylase gene, Amy1, has been shown to have multiple promoters, 
with the upstream promoter being stronger (32). In mouse and rat, 
the transcription of more than 100 times the amount of amylase RNA 
initiates from the upstream promoter (32). Expression of the c-myc 
gene also results from alternative promoters. In contrast, however, 
the difference in transcript concentrations may result from the 
stability conferred by the alternative leader sequences (33). Thus, 
it is possible that in the rat brain, cannabinoid receptor transcripts 
are produced in equal amounts but that they differ in their relative 
stabi I ities. 
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The half-life of mRNAs vary greatly; certain mRNAs are 
degraded in 20 minutes while other mRNAs have half lives of over 24 
hours (34). Since a single mRNA can be translated numerous times, 
ascertaining its half-life can give information regarding 
transcriptional stability. It is believed that mRNAs are not degraded 
until their poly-A tails are shortened to less than 10 nucleotides, a 
length that is incapable of binding to the poly-A binding protein with 
high affinity (35). Once the tail is shortened, mRNAs may be more 
susceptible to endonuclease attack and subsequent degradation. In 
this case, therefore, the rate at which RNA is degraded is controlled 
by the removal of the poly-A tail and the 5' sequence of two 
alternative transcripts, would not necessarily affect the 
deadenylation step (35). There is evidence, however, that a 
transcript must be translated before it is degraded (35). In this 
situation, the transcriptional stability would be inversely 
proportional to the translational efficiency of the message. 
Four features have been shown to effect translational 
efficiency (36). First, the presence of a methylated cap structure 
which is readily accessible seems to be a universal constant for 
eukaryotic mRNAs. The remaining three factors are a lack of 
secondary structure in the 5' leader sequence, the absence of AUG 
cedens upstream of the initiating AUG, and the length of the leader 
sequence. These factors are all directly related to the 5' leader 
sequence of an RNA molecule. 
The rate limiting step in translation is usually initiation (37). 
During initiation, the RNA comes in contact with the translational 
machinery. A long (> 100 nucleotides), unstructured leader sequence 
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has been shown to increase the rate of the translation (36). 
Initiation is thought to occur from the polyribosomes in concert 
with their cofactors, scanning the RNA for the first AUG codon. If 
the leader sequence contains excessive secondary structure the 
scanning process may be hindered. 
Secondary structure in the 5' leader is most often the cause of 
inefficient translation in eukaryotic mRNAs (36). Indeed the 
majority of eukaryotic mRNAs lack secondary structure in their 5' 
leader (38). 
Based on our data, it could be argued that transcript A would 
have a higher translational efficiency than transcript B. The 
presence of the GC rich region in the 5' untranslated sequence of 
transcript B could potentially form secondary structure which could 
hinder translation (36). Moreover, the 5' untranslated sequence of 
transcript A is longer than that of exon B. Having a long 5' 
untranslated sequence relatively free of secondary structure has 
been shown to enhance translational efficiency (36). Consequently, 
the higher translational efficiency of the A transcript could cause it 
to be degraded more quickly than the B transcript (35). This idea is 
consistent with the relatively high concentration of the B transcript 
compared to the A transcript that is found in rat brain (L.A. Matsuda, 
unpublished data). 
Until fairly recently it was assumed that the localization of 
proteins was due to signaling sequences on the nascent peptide. A 
protein's ultimate destination was believed to have no relationship 
to where the mRNA itself was translated. In 1987, evidence was 
provided that, in neurons, the mRNA, itself, may influence the 
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protein's final location. In a study tracking tritiated RNA through 
cultured hippocampal neurons, Davis et al. found that RNA from the 
nucleus was transported to dendrites. The transport rate was found 
to be 0.4 - 0.5 mm per day. This RNA transport could be blocked by 
metabolic inhibitors (39). 
The finding of polyribsomes In neuronal processes gave further 
credence for the theory that translation does not de facto occu r at 
the same sites for all mRNAs. In 1982, Bruckenstein et al. found 
polysomes selectively localized beneath synaptic junctions (40). If 
previous theory held true, there would be no rational explanation for 
translational machinery to be found outside the cell body. This 
finding supported the idea that mRNAs may exist which are 
transported to their final destination before they are translated. 
Although the exact mechanism of mRNA localization is still 
unknown, a model of how this may occur is presented in a review by 
Wilhelm (41). In this theory, mRNA associates with other 
ribonucleoproteins to form an RNP particle. The RNP particle IS 
actively translocated to its destination, and then anchors to the 
cytoskeleton. The evidence that mRNA transport is facilitated by 
RNPs was first demonstrated in oligodendrocytes. By visualizing 
fluorescently labeled myelin basic protein (MBP) mRNA, Ainger et al. 
(42) found the mRNA forming uniformly sized particles within 
minutes after being injected into oligodendrocytes. MBP mRNA, as 
seen by in situ hybridization, displayed a granular pattern in the 
cytoplasm. These granular particles were seen to be in close 
proximity to microtubules within the oligodendrocytes, suggesting 
that the cytoskeleton serves some anchoring function. 
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Several other studies have provided further evidence that 
there is direct contact between RNPs and the cytoskeleton. After 
disruption of the cell cytoskeleton, Davis et al. found RNA still 
bound to the cytoskeleton (39). Bassell et al. reported that in 
cultured cerebrocortical neurons poly A mRNA is associated with 
microtubules (43). In a study which compared differently localized 
mRNAs in primary neuronal cells, Litman et al. found mRNAs that are 
localized to the neuronal processes (tau and MAP2) are associated 
with microtubules. RNAs that encode proteins which are only found 
in the neuronal cell body (tubulin), however, were not found to be 
associated with microtubules (44). These findings suggest that 
microtubule association is necessary for transport of RNA to 
neuronal processes. 
It is believed that the microtubules and microfilaments found 
attached to the RNPs serve as "tracks" for their localization. 
Transport of these RNPs does not appear to be a random, diffusable 
process. Studying the progress of the fluorescently-Iabeled MBP 
mRNA Ainger et al. found the motion of the RNA from the cell body of 
oligodendrocytes through their long processes to the membrane 
sheets to be unidirectional (42). Davis' study also showed that the 
transport of RNA in hippocampal neurons is a neatly orchestrated, 
unidirectional process (39). 
The RNPs, therefore, appear to ultimately control the final 
location of the RNA. A signal which lies in the transcript itself 
appears to be responsible for the binding of the RNA to its "transport 
vehicle" (the RNPs). Wilhelm reviews a number of transcripts whose 
localization signals have been identified by comparing the transport 
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of the normal RNA with that of deletion mutants (41). In all known 
cases thus far, it appears that this signal is contained in the 3' 
untranslated region of the transcript. There are two alternative 
polyadenylation sites for the cannabinoid receptor transcript. These 
alternative sites result in two different 3' UTRs (15). It is 
therefore possible that the two transcripts may differ in their 
subcellular localization. 
The localization of the cannabinoid receptor and its RNA have 
been studied in the brain. Using a radiolabeled synthetic cannabinoid 
Herkenham et al. (45) found that binding is greatest in the 
cerebellum and the outflow nuclei of the basal ganglia. The 
molecular layer of the cerebellum contains the cannabinoid 
receptors (45), yet the majority of cannabinoid receptor RNA IS 
found in the granular layer (46). This mismatch between receptors 
and RNA is explained by the fact that the neurons in the granular 
layer project their axons to the molecular level. Similarly in the 
substantia nigra and globus pallidus, very high densities of 
receptors are found but little to no receptor RNA is detected (45, 
47). It seems plausible, therefore, that preferential localization of 
cannabinoid receptor mRNA to neuronal processes indeed occurs. 
Where the localization signal resides on the RNA or the protein 
itself has yet to be ascertained. 
In order to answer the many question involving the expression 
and regulation of the cannabinoid receptor gene, constructs must be 
made which delete certain segments of the A and B transcripts. Now 
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